Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Mylan Generics Will Be Distributed under Pfizer Brand Next Year: Pfizer’s Matsumori
July 17, 2013
- GSK Withdraws COPD Indication from NDA for ICS/LABA Combination Drug in Japan
July 17, 2013
- Astellas Launches Anticancer Agent Xtandi in UK
July 16, 2013
- Hisamitsu Initiates Domestic PII Study of Long-Acting Transdermal Allergic Rhinitis Treatment
July 16, 2013
- Manipulation of Data Cannot Be Confirmed Based on Results of University’s Investigation: Novartis Pharma
July 16, 2013
- Nippon Chemiphar Considers Establishing Manufacturing Base in Vietnam
July 16, 2013
- Otsuka Forms Clinical Research Firm in UK as Europe’s R&D Hub
July 12, 2013
- Cancer, CNS Diseases to Be Important Fields for MSD Over Next 10 Years: Pres. Alvarez
July 12, 2013
- Anti-HIV Treatment Prezista Naive Tablet 800 mg Approved: Janssen
July 12, 2013
- Daiichi Sankyo Voluntarily Recalls Mevalotin Granules 1% Due to Contamination with Vitamin Capsule
July 12, 2013
- Empagliflozin Alone Lowers Blood Glucose Level: BI, Eli Lilly
July 11, 2013
- Sanofi Begins Domestic PII Study of Vaccine Against CDIs
July 11, 2013
- Mediceo’s New Tokyo Logistics Center Completed, Operations to Start in September
July 11, 2013
- Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
- Sumitomo Bakelite Files Application for Gene Chip for Cancer Diagnosis
July 11, 2013
- Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
- PTH Preparations, New Drugs Grow in Intense Anti-Osteoporosis Drug Competition
July 10, 2013
- Kyowa Kirin Aims to Lead the Domestic Parkinson’s Disease Market in 5 Years on the Strength of Nouriast and 3 Other Products
July 10, 2013
- Will the ARB Market Regain Steam in FY2013? Leading ARB Drug Marketers Forecast Double-digit Growth in FY2013
July 10, 2013
- High Price, Concerns About Safety Could Pose Hurdle to Success of Pfizer Japan’s Xeljanz
July 10, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…